Currently, enrollment to trials depends on a patient’s type of cancer, or genetic data obtained from an invasive tumour biopsy, which may not represent a patient’s current disease. According to research published in Nature Medicine, scientists could help match cancer patients with no other treatment options to clinical trials by analyzing the genetic faults in a sample of their blood. (Medical Xpress)